Table 2. Overall tumour response to immunotherapy and hepatic arterial infusion chemotherapy in HCC patients with MVI.
| Response | Overall RECIST, n (%) | Overall mRECIST, n (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HAIC (n=70) | Systemic ICI (n=46) | HAIC and ICI (n=14) | P value | HAIC (n=70) | Systemic ICI (n=46) | HAIC and ICI (n=14) | P value | ||
| CR | 0 (0.00) | 0 (0.00) | 1 (7.14) | 0.108 | 0 (0.00) | 1 (2.17) | 1 (7.14) | 0.088 | |
| PR | 16 (22.86) | 12 (26.09) | 6 (42.86) | 0.299 | 17 (24.29) | 12 (26.09) | 6 (42.86) | 0.355 | |
| SD | 13 (18.57) | 6 (13.04) | 2 (14.29) | 0.717 | 12 (17.14) | 5 (10.87) | 2 (14.29) | 0.645 | |
| PD | 41 (58.57) | 28 (60.87) | 5 (35.71) | 0.230 | 41 (58.57) | 28 (60.87) | 5 (35.71) | 0.230 | |
| ORR | 16 (22.86) | 12 (26.09) | 7 (50.00) | 0.111 | 17 (24.29) | 13 (28.26) | 7 (50.00) | 0.150 | |
| DCR | 29 (41.43) | 18 (39.13) | 9 (64.29) | 0.230 | 29 (41.43) | 18 (39.13) | 9 (64.29) | 0.230 | |
CR, complete response; DCR, disease control rate; HAIC, hepatic arterial infusion chemotherapy; HCC, hepatocellular carcinoma; ICI, immune checkpoint inhibitor; MVI, macrovascular invasion; ORR, objective response rate; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumours; mRECIST, modified Response Evaluation Criteria in Solid Tumours; SD, stable disease.